Sort
10,766 grants matching “checkpoint inhibitor”
Definition of Immune Infiltrate Phenotype and DNA Damage Response Deficits Across Diverse Murine Mammary Carcinomas
$494,120Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2022 · CA
Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin
$494,107Konstantinos Votanopoulos · Wake Forest University Health Sciences · R01 · FY2025 · CA
Role of meningeal lymphatic vasculature in neuroimmune communication development
$494,067Jean-Leon Thomas · Yale University · R01 · FY2025 · NS
Metabolic basis of ARID1A-mutated ovarian cancer
$494,032Rugang Zhang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Molecular Mechanisms of Bladder Cancer Immunometabolism
$493,870Liuqing Yang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma
$493,861Abraham Ari Hakimi · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Molecular Targeting of Diffuse Large B-cell Lymphoma
$493,670Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R01 · FY2013 · CA
Evaluation of Immune-based Combinations in Prostate Cancer
$493,445Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Molecular Genetics of HNPCC
$493,284Marsha L. Frazier · University Of Tx Md Anderson Can Ctr · R01 · FY2008 · CA
Project 1: Investigation of immune and stromal factors that promote prostate adenocarcinoma progression and castration response
$493,245Charles L Sawyers · Columbia University Health Sciences · P01 · FY2023 · CA
TRAIL-induced Cell Death in Breast Cancer Cells
$493,195Stanley Lipkowitz · Division Of Clinical Sciences - Nci · ZIA · FY2014 · CA
TASK ORDER: FURTHER TESTING OF A MULTI-PEPTIDE KRAS VACCINE FOR PANCREATIC CANCER PREVENTION
$493,001Venkateshwar Chinthalapally · University Of Oklahoma Hlth Sciences Ctr · N01 · FY2020 · CA
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion
$492,997Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2025 · AI
The Adenosinergic Pathway in Tumor-derived Exosomes
$492,737Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
$492,647Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R01 · FY2017 · CA
Exploring the potential of TET inhibition in cancer immunotherapy
$492,576Anjana Rao · La Jolla Institute For Immunology · R01 · FY2022 · CA
Exploring the potential of TET inhibition in cancer immunotherapy
$492,576Anjana Rao · La Jolla Institute For Immunology · R01 · FY2023 · CA
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer
$492,054Ralph P Mason · Ut Southwestern Medical Center · R01 · FY2020 · CA
Project 2: Targeting differentiation-linked redox sensitivity in melanoma
$492,027Thomas G Graeber · University Of California Los Angeles · P01 · FY2024 · CA
Project 1: Strategies to enhance MEK inhibitor efficacy in MUTNRAS melanoma
$492,026Roger S Lo · University Of California Los Angeles · P01 · FY2024 · CA
Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
$491,988Robert L Ferris · University Of Pittsburgh At Pittsburgh · R01 · FY2016 · CA
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
$491,792Xiongbin Lu · Indiana University Indianapolis · R01 · FY2023 · CA
Defining the Pathogenesis and Prognosis of Human Acute Interstitial Nephritis
$491,708Lloyd G Cantley · Yale University · R01 · FY2023 · DK
CD206 activators as novel immunomodulators
$491,448Juan Marugan · National Center For Advancing Translational Sciences · ZIA · FY2024 · TR
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors
$491,406Seth M Pollack · Northwestern University At Chicago · R01 · FY2022 · CA